GENETIC VARIANTS IN IL-6, P53, MMP-9 AND CXCR PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER TREATED WITH ANTI-VEGF THERAPY

摘要

The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.